Research on Pathways to Improve Innovative Drug Accessibility from the Perspective of Policy Synergy: A Review and Prospect

Yiyang Ren; Wenxi Tang

doi:10.6981/FEM.202604_7(4).0003

Authors

Yiyang Ren
Wenxi Tang

DOI:

https://doi.org/10.6981/FEM.202604_7(4).0003

Keywords:

Innovative Drug Accessibility; Policy Coordination; Evaluation Mechanism.

Abstract

High-cost innovative medicines is a global priority, prompting China's policy framework to shift from singular price controls toward integrated coordination and value-based approaches. This review examines theoretical mechanisms and empirical evidence regarding policy synergy's impact on drug accessibility. While existing research provides robust theoretical foundations, challenges remain regarding fragmented evaluation systems, limited empirical scope, and inadequate micro-level equity analysis. Future research should advance policy synergy theory, quantitative assessment methodologies, patient-centered equity studies, and dynamic adjustment mechanisms to support evidence-based policy optimization during the 14th Five-Year Plan period.

Downloads

Download data is not yet available.

References

[1] World Health Organization, Health Action International. Measuring Medicine Prices, Availability, Affordability and Price Components[R]. Geneva: WHO, 2008.

[2] Gong S W, Xu Y, Zhang L. Research on the evaluation index system of drug accessibility[J]. Chinese Health Economics, 2011, 30(05): 72-74.

[3] Widdus R. Public-private partnership for health: their main targets, their diversity, and their future directions[J]. Bull World Health Organ, 2001, 79(8): 713-720.

[4] Li W, Chen H D, Lu W, et al. Research on the accessibility of national reimbursement negotiated drugs from 2016 to 2021: An empirical analysis based on national big data[J]. Chinese Journal of Modern Applied Pharmacy, 2023, 40(10): 1405-1410.

[5] Zhuang J. Research on legal issues of drug accessibility in China[D]. Beijing: Peking University, 2005.

[6] Challis L, Fuller S, Henwood M, et al. Joint Approaches to Social Policy: Rationality and Practice[M]. Cambridge: Cambridge University Press, 1988.

[7] Guerrero OA, Castañeda G. Quantifying the coherence of development policy priorities[J]. Development Policy Review, 2021, 39(2): 155-180.

[8] Peng J S, Zhong W G, Sun W X. Policy measurement, evolution of policy synergy and economic performance: An empirical study based on innovation policy[J]. Management World, 2008(9): 25-36.

[9] Li H. On synergistic government[D]. Changchun: Jilin University, 2010.

[10] OECD. Pharmaceutical Pricing and Reimbursement Policies in Mexico[R]. Paris: OECD Publishing, 2007.

[11] Roy A, Kumar A, Srivastava AK. Disparities in Access to Essential Medicines in India: A Systematic Review of Availability, Affordability and Policy Challenges[J]. International Journal of Scientific Research and Reviews, 2023.

[12] Gao X, Yu M, Sun Y, et al. New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study[J]. Risk Management and Healthcare Policy, 2024, 17: 3241-3252.

[13] Tan Q L, Guo R Y, Sun H L, et al. Synergistic effects of centralized volume-based procurement and medical insurance negotiation policies[J]. China Pharmacy, 2021, 32(15): 1793-1799.

[14] Duan D, Yang Y. Impact of combined medication payment management policies on population health performance[J]. PLoS One, 2026, 21(1): e0330057.

[15] Howlett M, Rayner J. Design principles for policy mixes: Cohesion and coherence in ‘new governance arrangements’[J]. Policy and Society, 2007, 26(4): 1-18.

[16] Xiang G C, Liu Y Q, Wang D, et al. Research on synergistic incentive mechanisms between national public hospital performance assessment and medical insurance payment reform[J]. Chinese Health Economics, 2026, 45(1): 10-13.

[17] May P J, Sapotichne J, Workman S. Policy Coherence and Policy Domains[J]. Policy Studies Journal, 2006, 34(3): 381-404.

[18] Niu B, Liu T T, Zhang Y Q, et al. Analysis of synergistic effects between NRDL and CVP policies: Based on the achievements and evolution of national medical insurance negotiations[J]. China Health Insurance, 2025(8): 39-52.

[19] Lu M Q, Jiang L T, Wu L Q. Research on the synergy mechanism between medical insurance drug catalog access pathways and centralized volume-based procurement policies in China[J]. Chinese Journal of Health Policy, 2025, 18(5): 1-8.

[20] Wang H, Huo Y T, Zhuang Q. Research on the essential medicines system from the perspective of synergy with centralized volume-based procurement policy[J]. China Pharmacy, 2023, 34(18): 2177-2181.

[21] Barwick PJ, Swanson AT, Xia T. A Double Dose of Reform: Insurance and Centralized Negotiation in Drug Markets[R]. NBER Working Paper No. 33832, National Bureau of Economic Research, 2025.

[22] Zhong W G, Peng J S, Sun W X. Policy measurement, policy synergy and technological performance: An empirical study based on China's innovation policy (1978-2006)[J]. Science of Science and Management of S.&T., 2009(3): 54-60.